Drug intelligence / Profile preview

MAb-02-X1.2

Development stage: Preclinical
Lead developer: MedAbome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb-02-X1.2 is a monoclonal antibody currently in preclinical development by MedAbome for the treatment of solid tumors and hematologic malignancies. It is part of the company's MAb-02-X1 series of oncology candidates. While the specific molecular target of MAb-02-X1.2 remains undisclosed by the developer, the antibody is designed to address a range of liquid and solid cancers. The program is currently undergoing preclinical evaluation to establish its safety and efficacy profile prior to potential clinical advancement.

Beyond the preview

Go deeper on MAb-02-X1.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb-02-X1.2.

Explore the full profile